FDA warns Betone S.A. de C.V. over manufacturing violations for OTC antiseptic wipes, including subpotent active and missing glycerin safety tests.
What happened
FDA inspected Betone S.A. de C.V.'s drug manufacturing facility from November 6 to 10, 2023, and reviewed the company's December 1, 2023 response. FDA found violations of current good manufacturing practice (CGMP), the rules for drug manufacturing: missing release testing, subpotent formulation, inadequate component testing including glycerin for DEG/EG, and insufficient stability testing.
What FDA found
The company did not test each batch for identity and strength of the active ingredient before releasing it.
21 CFR 211.165(a)The company made wipes with less active ingredient than the labeled amount.
21 CFR 211.101(a)The company did not adequately test incoming components for identity and conformity, and did not establish the reliability of suppliers' certificates of analysis.
21 CFR 211.84(d)(1) and 211.84(d)(2)The company did not perform the USP identity test on each glycerin shipment or lot to detect diethylene glycol (DEG) or ethylene glycol (EG).
21 CFR 211.84(d)(1) and 211.84(d)(2)The company did not have stability testing adequate to support the expiration dates on its distributed drug products.
21 CFR 211.137(a)The label for DODY’S Antiseptic Hand Sanitizer Wipes suggests use as an antiseptic wash, which conflicts with wipe directions and dosage form.
section 505G of the FD&C Act
What FDA wants
Respond in writing within 15 working days with corrective actions and preventive actions. Provide DEG and EG test results from retained high-risk component lots, or testing of implicated finished batches, no later than 30 calendar days from the date of the letter.
Who should pay attention
- brands that buy OTC wipes from this contract manufacturer
- retailers and distributors selling DODY’S antiseptic wipes
- companies sourcing glycerin or other high-risk components from suppliers that rely on certificates of analysis
This is a summary. Read the original letter on fda.gov.